Source comparison
Peptides for Stomach Ulcers Compared: Efficacy Comparison
Primary Mechanism VEGF/FGF upregulation, angiogenesis, direct mucosal repair Actin polymerization, NF-κB downregulation, systemic inflammation reduction BPC-157 accelerates tissue regeneration; TB-500 modulates chronic inflammation Use BPC-157 for acute injury
This comparison does not assign a generated winner or score.
- Primary Mechanism
- VEGF/FGF upregulation, angiogenesis, direct mucosal repair
- Actin polymerization, NF-κB downregulation, systemic inflammation reduction
- BPC-157 accelerates tissue regeneration; TB-500 modulates chronic inflammation
- Use BPC-157 for acute injury, TB-500 for chronic inflammatory states
- Bioavailability Route
- Oral or subcutaneous. Acid-stable peptide
- Subcutaneous/intramuscular only. Oral degradation
- BPC-157 can be dosed orally for gastric targets; TB-500 requires injection
- Oral convenience favors BPC-157 for gastric lesions
- Onset of Effect
- 3–7 days (measurable ulcer reduction)
- 10–21 days (inflammatory marker reduction)
- BPC-157 shows rapid localized repair; TB-500 acts cumulatively over weeks
- BPC-157 for rapid symptom resolution; TB-500 for long-term management
- Dosing Frequency
- Once daily, 7–14 day cycles
- 2–3x weekly, 4–6 week cycles
- BPC-157 requires shorter, more frequent dosing; TB-500 uses weekly protocols
- BPC-157 is more intensive; TB-500 fits maintenance protocols
- Preclinical Ulcer Reduction
- 70–87% ulcer area reduction in 14 days
- 40–55% inflammatory cytokine reduction in 21 days
- BPC-157 shows direct tissue-level outcomes; TB-500 shows systemic inflammatory metrics
- BPC-157 outperforms in acute ulcer healing endpoints
- Application for H. pylori-Associated Ulcers
- Limited direct antibacterial effect; supports repair post-eradication
- Reduces inflammation that perpetuates ulceration during active infection
- Neither peptide eradicates H. pylori. Both support healing in different phases
- Use BPC-157 post-eradication; TB-500 during chronic inflammatory phase